内容紹介
A Case of HER2-Positive Breast Cancer for Which Preoperative Chemotherapy with Pertuzumab Resulted in a Pathological Complete Response
Summary
A right breast tumor was identified during screening in a 56-year-old woman, and she was then diagnosed with Stage ⅡB breast cancer(T2N1M0)of Luminal-HER2 type. She was treated with preoperative chemotherapy with pertuzumab, trastuzumab, and docetaxel followed by epirubicin, cyclophosphamide, and fluorouracil. She was judged to have achieved a clinical complete response after 4 courses of pertuzumab, trastuzumab, and docetaxel, and she then underwent partial resection of the right breast and sentinel lymph node dissection. Pathological examination revealed that a pathological complete response was achieved. Combination therapy with pertuzumab, trastuzumab, and docetaxel seems to be a useful preoperative chemotherapy regimen for HER2-positive breast cancer.
要旨
症例は56歳,女性。乳がん検診で右乳腺腫瘍を指摘され,当科紹介となった。右乳房C領域に4 cmの不整な分葉状腫瘍を認め,腋窩リンパ節腫大も認めた。浸潤性乳管癌(乳頭腺管癌),Luminal-HER2タイプのT2N1M0,StageⅡB乳癌と診断された。術前化学療法としてpertuzumab+trastuzumab+docetaxelを4コース施行し,cCRとなった。その後にFEC療法4コースを追加し,乳房部分切除およびセンチネルリンパ節生検を行った。切除標本には腫瘍の遺残を認めず,pCRと判断された。pertuzumabを用いた術前化学療法は,HER2陽性乳癌に対する術前化学療法に有効な治療法と考えられた。
目次
Summary
A right breast tumor was identified during screening in a 56-year-old woman, and she was then diagnosed with Stage ⅡB breast cancer(T2N1M0)of Luminal-HER2 type. She was treated with preoperative chemotherapy with pertuzumab, trastuzumab, and docetaxel followed by epirubicin, cyclophosphamide, and fluorouracil. She was judged to have achieved a clinical complete response after 4 courses of pertuzumab, trastuzumab, and docetaxel, and she then underwent partial resection of the right breast and sentinel lymph node dissection. Pathological examination revealed that a pathological complete response was achieved. Combination therapy with pertuzumab, trastuzumab, and docetaxel seems to be a useful preoperative chemotherapy regimen for HER2-positive breast cancer.
要旨
症例は56歳,女性。乳がん検診で右乳腺腫瘍を指摘され,当科紹介となった。右乳房C領域に4 cmの不整な分葉状腫瘍を認め,腋窩リンパ節腫大も認めた。浸潤性乳管癌(乳頭腺管癌),Luminal-HER2タイプのT2N1M0,StageⅡB乳癌と診断された。術前化学療法としてpertuzumab+trastuzumab+docetaxelを4コース施行し,cCRとなった。その後にFEC療法4コースを追加し,乳房部分切除およびセンチネルリンパ節生検を行った。切除標本には腫瘍の遺残を認めず,pCRと判断された。pertuzumabを用いた術前化学療法は,HER2陽性乳癌に対する術前化学療法に有効な治療法と考えられた。